Background
==========

The dissemination of Methicillin Resistant *Staphylococcus aureus*(MRSA) in hospitals is a growing problem worldwide. In The Netherlands, a search and destroy policy is implemented \[[@B1]\]. Patients colonized with MRSA are kept in isolation until they are culture negative. A MRSA negative report can faster be obtained by PCR. Therefore, a molecular approach for negative screening of MRSA was exploited. Molecular detection of the *mecA*gene, which confers resistance to all β-lactams, has often been used in combination with other *S. aureus*specific genes in a multiplex PCR. Genes that are specific for *S. aureus*comprise for example of the sequence published by Martineau et al. \[[@B2]\], the nuclease gene (*nuc*) \[[@B3],[@B4]\], or the coagulase gene (*coa*) \[[@B5]\]. When clinical samples contain a mixture of coagulase negative staphylococci (CNS), methicillin sensitive *S. aureus*(MSSA), and MRSA, a positive *mecA*PCR can be generated by CNS while both MSSA and MRSA generate a positive PCR for the *coa*or the *nuc*gene. Only culturing could confirm MRSA. Another approach for detection of MRSA was presented by a multiplex PCR described by Huletsky et al. \[[@B6]\]. This PCR specifically targets the junction between a conserved open reading frame *orfX*in *S. aureus*, and the staphylococcal cassette chromosome containing the *mecA*gene (SCC*mec*). For MRSA, 8 different types of SCC*mec*elements have been classified \[[@B7]\]. The SCC is known to be a mobile heterogeneous genetic element that integrates site specifically into *orf*X. SCC*mec*is an SCC containing the *mec*A gene. SCC can also be present in CNS, not containing *mecA*but integrated into the analogous chromosomal location. MSSA can contain non-*mecA*-SCC or SCC*mec*elements which have lost the region containing *mecA*. Several commercially available molecular screening tests are based on PCR amplification of the chromosome-SCC*mec*junction.

In this study, a novel DNA extraction method for MRSA was adopted that virtually prevents PCR inhibition. The detection process was fully automated for high through-put of clinical materials. An extra 17 forward primers were added to PCR to detect several newly identified MRSA strains in this study carrying SCC*mec*variants and found to be present in The Netherlands, and possibly elsewhere. An adaptable PCR format is needed for reliable detection of all MRSA.

Findings
========

Implementation and evaluation of *orfX*/SCC*mec*PCR
---------------------------------------------------

The PCR as described by Huletsky et al. \[[@B6]\], was slightly adapted (Table [1](#T1){ref-type="table"}).

###### 

Primer and probe sequences used in OrfX-SCC PCR

  primer/probe   Sequence 5\'-3\'                    Reference
  -------------- ----------------------------------- ------------------------------
  F1             GTCAAAAATCATGAACCTCATTACTTATG       according to Huletsky et al.
                                                     
  F2             AATATTTCATATATGTAATTCCTCCACATCTC    adapted from Huletsky et al.
                                                     
  F3             CTTCAAATATTATCTCGTAATTTACCTTGTTC    adapted from Huletsky et al.
                                                     
  F4             CTCTGCTTTATATTATAAAATTACGGCTG       according to Huletsky et al.
                                                     
  F5             TCACTTTTTATTCTTCAAAGATTTGAGC        adapted from Huletsky et al.
                                                     
  F7             CCATTTCTTCCAAAAAATATATTTACTTTAGTC   This study
                                                     
  F8             TTTCATAATATGTGCTACGCAACCTA          This study
                                                     
  F9             CGAGTTAATTTTTTATTTTAGAGCGCTTAC      This study
                                                     
  F10            CCGCTCCTTTTATATTATACACAACCTATT      This study
                                                     
  F11            GCCATATTAATGCCTCACGAAAC             This study
                                                     
  F12            CATTCATTAACATCGTACTCTGCATTT         This study
                                                     
  F13            TCCCTTTATGAAGCGGCTGAA               This study
                                                     
  F14            AAGCTATAGTTCAGCATTATCGTAAGTTAACT    This study
                                                     
  F15            TGCCAATCACAGTTCAATCAATTATT          This study
                                                     
  F16            TCCTTTCTAATTATATTATGCGCAACCT        This study
                                                     
  F17            ACTCTGATAAGCCATTCATTCATCCA          This study
                                                     
  F18            ACAATCCTAACATAAGATTGTGGCTTT         This study
                                                     
  F20            GCATATTCACTTTGATAAGCCATTCAT         This study
                                                     
  F21            CGGTTCTGATATCTTTTCAACCATT           This study
                                                     
  F23            CCCCTCCCATTAACTCCGTATAT             This study
                                                     
  F24            CCCAAACTCTTAACTTTCTTCAATACATT       This study
                                                     
  F25            TTCTAAGGTAGCTTCCCTTTCAATAATTT       This study
                                                     
  R1             CGTCATTGGCGGATCAAAC                 adapted from Huletsky et al.
                                                     
  R2             CGTCATTGGTGGATCAAACG                adapted from Huletsky et al.
                                                     
  probe2         FAM-CACAAGGATGTCTTACAACG-MGB        adapted from Huletsky et al.
                                                     
  probe3         FAM-CACAAGGACGTCTTACAACG-MGB        adapted from Huletsky et al.
                                                     
  probe4         FAM-CACAAAGACGTCTTACAACG-MGB        adapted from Huletsky et al.

To allow PCR detection of more MRSA types, a literature search was conducted. Forward primer F7 was derived from the sequence of *S. aureus*strain JCSC 3624 (WIS), accession number AB121219 \[[@B8]\], and was included in the PCR. Primer F10 was designed based on the sequence of *S. aureus*U10927 \[[@B9]\] (Table [1](#T1){ref-type="table"}).

With the expanded *orfX*/SCC*mec*PCR a total of 1906 samples was investigated with high through-put screening; 303 were PCR positive, no inhibition of PCR was found. To verify whether a positive signal was due to viable or dead MRSA, all were cultured; 141 were culture positive, and 22% of 141 were found to be MSSA. The latter may have lost *mecA*regions or contain non-*mecA*SCC elements. All culture positive MRSA were confirmed by *mecA/coa*PCR. Thus, PCR is highly non specific. However, since all suspect samples are subsequently cultured, this is acceptable. With negative screening it is important that the negative predictive value is 100%.

One MRSA isolate found by routine culture was negative in PCR. We analyzed the sequence of this strain (303480, Table [2](#T2){ref-type="table"}) by genomic DNA sequencing with primer R1. A sequence of 345 bp was obtained which was aligned to Genbank/EMBL DNA sequences using BLAST. No significant sequence homology was found except that the 35 bp flanking *orfX*showed 97% homology with a repeated sequence found in *S. haemolyticus*(AP006716;bp 52313, and 91034), also present in *S. saprophyticus*(AP08934;bp 50105). A new primer in PCR (primer F8, Table [1](#T1){ref-type="table"}) was derived from the obtained sequence. To minimize the chance for more false-negative PCR results for MRSA, other laboratories in The Netherlands were asked for MRSA strains that were negative in commercial molecular tests used by these laboratories. We received a total of 86 clinical isolates or DNA. Whenever a strain was also negative in our *orfX*/SCC*mec*PCR, DNA was sequenced and a new primer was added to PCR. Of 86 strains, another 14 additional forward primers were designed, apart from 2 literature based primers, and 1 primer based on a MRSA strain from our own hospital. All 17 primers were included in PCR to a total of 22 forward primers (Table [1](#T1){ref-type="table"}).

###### 

Observed sequence homologies of analyzed MRSA strains from various locations, length of DNA sequence analysis reads, and PCR primers based on these sequences

  Strain      Location      bp    Homology (%) with accession number (species) corresponding to bp   primer
  ----------- ------------- ----- ------------------------------------------------------------------ --------
  02M023064   Breda         222   94% U10927 (*S. aureus*);bp 648-426                                F9
                                                                                                     
  JBZ12       Den Bosch     235   93% AB539727 (*S. aureus*);bp 84645-84507                          F13
                                                                                                     
  261207168   Enschede      834   91% AB063172 (*S. aureus*); bp 169-879                             F15
                                                                                                     
  JBZ33       Den Bosch     396   99% EU272080 (*S. aureus*);bp 794-399                              F23
                                                                                                     
  S0121       Utrecht       280   100% EU263618 (*S. aureus*);bp 655-376                             F17
                                                                                                     
  CC8         Denmark ( )   422   99% BK001539 (*S. epidermidis*);bp 19437-19016                     F20
                                                                                                     
  434-1819    Eindhoven     416   99% BK001539 (*S. epidermidis*);bp 34917-34205                     F24
                                                                                                     
  S0089       Utrecht       409   100% AP006716 (*S. haemolyticus*);bp 52718-52358                   F16
                                                                                                     
  582         Utrecht       344   98% AP006716 (*S. haemolyticus*);bp 91374-91031                    F18
                                                                                                     
  060120      Leiden        912   98% AP006716 (*S. haemolyticus*);bp 30663-29755                    F25
                                                                                                     
  303480      Rotterdam     345   CGCAACCTATTTTTTAGTTTTATTTGTGATAtGCT                                F8
                                                                                                     
  251110219   Enschede      900   CAACtTATTTTTTAGTTTTATTTGTGATACGCTTCT                               F14
                                                                                                     
  JBZ54       Den Bosch     688   No significant homology found                                      F21
                                                                                                     
  40295861    Breda         417   No significant homology found                                      F11
                                                                                                     
  40461611    Breda         762   No significant homology found                                      F12

Sequence analysis of PCR negative MRSA strains
----------------------------------------------

All 14 strains mentioned above were verified to be MRSA using *mecA/coa*PCR. All were positive in both PCRs. The results of DNA sequence analysis are presented in Table [2](#T2){ref-type="table"}. BLAST comparisons were made with the sequences cut off at the *orfX*according to Ito et al. \[[@B10]\]. Within the *orfX*gene, the obtained sequences were highly homologous and consistently aligned to *S. aureusorfX*.

The SCC*mec*of 5 strains showed various degrees of homology (91-100%) with different parts of SCC*mec*sequences of *S. aureus*strains. Two MRSA strains showed 99% homology with *S. epidermidis*SCC, but with different regions. Another 3 strains were homologous to *S. haemolyticus*in their *orfX*flanking sequences. BLAST alignments of strains 303480 and 251110219 showed no significant sequence homologies except for a 35 bp repeat (CAACtTATTTTTTAGTTTTATTTGTGATACGCTTCT)found present in *S. haemolyticus*and *S. saprophyticus*. The *orfX*flanking regions of 3 other strains showed no significant homology to any Genbank/EMBL sequences.

Comparison of right SSC*mec*-OrfX junctions
-------------------------------------------

The alignment of right SCC*mec*-OrfX junctions is shown in Figure [1](#F1){ref-type="fig"}. The direct repeat consensus (\--A-TT-TGATA-GC-TC, \[[@B10]\]) is largely intact, suggesting that SCC sequences from *S. epidermidis*and *S. haemolyticus*were acquired by recombination rather than by transposition.

![**Alignment of right SCC-OrfX junctions**. Strains are designated by the primers based on their sequences. OrfX starts at bp 55 (according to Ito et al. \[[@B10]\]. SA; *S. aureus*, SE; S*. epidermidis*, SH; *S. haemolyticus*, SR; Staphylococcal repeats. Strains without any homology to known sequences were omitted from the comparison.](1756-0500-4-150-1){#F1}

Discussion
==========

The staphylococcal cassette chromosome SCC*mec*is a genetic mobile element that contains the methicillin resistant *mecA*gene \[[@B8]\]. Its site-specific insertion or excision is mediated by cassette chromosome recombinase (ccr) complex and by the presence of direct and inverted repeats at the SCC*mec*extremities. The combination of classes of *mec*gene complex and *ccr*gene complex forms the basis of their classification \[[@B10]\]. At present 8 types of SCC*mec*elements have been classified \[[@B7],[@B11]\]. In addition, SCC*mec*can harbour other drug resistant genes, and insertion sequence elements (*IS*431, *IS*1272), transposons (Tn4001, Tn554) or plasmids (pUB110, pT181). The chromosome flanking regions (junction or J-regions, formerly, junkyard regions) of SCC*mec*are most variable in their DNA sequences.

We adapted the PCR described by Huletsky et al. \[[@B6]\], based on amplification of the chromosome-SCC*mec*junction. We initially included 2 more forward primers to expand detection to MRSA known from literature. After sequence analysis of 14 MRSA strains that were not recognized by the initial primer set, we included additional primers resulting in a megaplex PCR with 14 primers based on sequences of newly identified MRSA with variant SCC*mec*sequences to a total of 21 forward primers. No adverse effects on PCR were seen with this number of primers.

From 3 strains the sequenced SCC*mec*region did not match any known DNA sequence, presuming a non-human relation. In The Netherlands live-stock associated MRSA is increasingly isolated \[[@B12]\]. Reischl et al. \[[@B13]\] have shown that live-stock associated MRSA can be discriminated on the basis of a G→A mutation in *orfX*. Based on the finding that these strains were only positive in PCR when the probe harbouring this mutation (probe 2) was used, we confirmed that these 3 strains were most probably live-stock associated MRSA.

In the SCC*mec*of the other new strains, repeated sequences as *IS*431 and *IS*1272 were found. IS elements are mobile and can move by transposition. The similar but not identical repeats found in strain 303480 and 251110219, might be related to an *IS*1272 encoded truncated transposase as was indicated by BLAST homology. This suggested that the variant SCC*mec*sequences resulted from transposition. Therefore the right chromosome-SCC*mec*junctions carried by the new MRSA strains were compared. The consensus represented the direct repeat (DR) involved in insertion and excision of SCC*mec*. Consequently, the variant SCC*mec*sequences were acquired by recombination rather than transposition. Mongkolrattanothai et al. \[[@B14]\], reported a non-*mecA*-SCC element present in *S. epidermidis*with 3 DR highly homologous to *S. aureus*, 2 at the extremities of the element and 1 in the middle. The 2 MRSA strains carrying different SCC homologs of *S. epidermidis*in this study, were each highly homologous to the SCC described by Mongkolrattanothai \[[@B14]\], but represented the sequence on either side of the middle DR. This finding may corroborate the recombination theory, regardless of the orientation of the inserted SCC in the 2 MRSA strains. Whether *mecA*is carried on the acquired SCC from *S. epidermidis*of the MRSA strains found in our study, as well as SCC typing, remains a topic for future studies.

In conclusion, it appears that MSSA can convert to MRSA by acceptance of SCC sequences from CNS. This process may be driven by selection pressure of antibiotics. Indeed, an isogenic pair of MSSA and MRSA was recently described that supports the occurrence of horizontal transfer of SCC*mec*between Staphylococcal species \[[@B15]\]. The 86 strains not detected as being MRSA in other laboratories by commercially available tests raises concern about their performance \[[@B16],[@B17]\]. Exploiting the SCC*mec*junction as target in PCR used for detection of MRSA requires continuous awareness of possible variants. PCR based on *mecA*/*nuc*gene does not seem to present an acceptable alternative because the *nuc*gene may be absent as has been found earlier \[[@B18]\]. The *mecA*/*coa*PCR, combined with chromosome-SCC*mec*junction PCR identifies other MRSA variants that may arise.

Conclusions
===========

We identified 14 new variant chromosome-SCC*mec*junctions in MRSA, that are not detected in commercially available MRSA detection kits. We adapted our PCR to detect all known variant chromosome-SCC-*mec*types of MRSA.

Fully automated high through-put detection and robust DNA extraction support an adaptable PCR format for detection of these newly identified MRSA strains. Moreover, this system can easily be expanded with novel PCR primers when new variants of chromosome-SCC*mec*types in MRSA may arise.

Methods
=======

Clinical samples
----------------

Samples were taken from nose, throat, and perineum, and if appropriate also from wounds, sputum, and catheters (Transwab, Medical Wire & Equipment Co. Ltd., Corsham, Wilts., England) in the context of patient and personnel screening as required by the Dutch policy for MRSA control. Since no extra action or sampling was requested than the medically indicated, informed consent was not asked and no ethical approval was required, in conformity to the guidelines of the Dutch Central Committee on Research involving Human Subjects. Swabs were inoculated into 5 ml phenyl mannitol broth (PHMB) containing ceftizoxime and aztreonam \[[@B19]\] for overnight incubation. After at least 18 hours of incubation, PHMB broth was subjected to PCR.

Automated DNA isolation, PCR detection, and data output by MRSA-screen with PCR amplification of OrfX-SCC*mec*junction
----------------------------------------------------------------------------------------------------------------------

PHMB tubes were placed into the MultiPROBE II PLUS HT Expanded pipetting robot (PerkinElmer Life and Analytical Sciences). This system is equipped with a bar-code reader and automated plate sealer (RoboSeal). This system handles the DNA extraction, PCR assay set-up, and sealing of the plate. Next, the plates are automatically transferred to a real-time ABI 7900HT thermocycler (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Thus, barcode scanning, DNA extraction, pipetting, sealing of the 384-well PCR Plate, creating a run file and starting the PCR, were done by the system without interference or need of presence of a technician. Results were automatically transferred to the Laboratory Information System.

Software was programmed by PerkinElmer to perform the following steps. After barcode reading, 5 ml of saline was added and mixed by pipetting. This 1:1 dilution served to elevate the fluid level and to prevent the 9.5 cm long probes touching the swabs in the 15 cm long tubes.

Template DNA was prepared by using the Extract-N-Amp™ Plant PCR Kit (SIGMA, Munich, Germany). In short, 50 μl sample was mixed with 100 μl SIGMA Extraction Solution (E7526). The mixture was incubated at 95 °C for 10 minutes, cooled to room temperature, 100 μl SIGMA Dilution Buffer (D5688) was added and mixed. This DNA sample is PCR ready when used in combination with the SIGMA Extract-N-Amp PCR ReadyMix™ (E3004).

Primers and probes for detection of the OrfX-SCC*mec*junction were used in one primer-probe mixture with the following concentrations; 600 nM for each F and R primer, and 120 nM for each probe (Table [1](#T1){ref-type="table"}). Each sample was tested with this primer-probe mixture. Amplification reactions were performed in a volume of 20 μl, with 10 μl SIGMA Extract-N-Amp PCR Reaction Mix™ (including 4% Reference Dye) in 6 μl primer-probe mix and 4 μl of the DNA sample. Amplification consisted of 3 min at 95 °C followed by 44 cycles of 15 s at 95 °C and 60 s at 60 °C. In each run a MRSA positive and a negative control was included. A sample was regarded suspect for MRSA in the MRSA-screen if the PCR was positive. Positive samples were subsequently cultured on blood agar plates.

*MecA/coa*gene PCR
------------------

The *mecA*PCR was carried out as described \[[@B4]\], with 800nM of each primer. PCR for *coa*was as described previously \[[@B5]\]. The concentration of primers Coag2: CGAGACCAAGATTCAACAAG, and Coag3: AAAGAAAACCACTCACATCA was 800nM each. *MecA/coa*PCR was used to confirm MRSA isolates. Results of *mecA*and *coa*PCR were analyzed using agarose gel electrophoresis.

DNA sequence analysis
---------------------

Sequence analysis was performed by Baseclear, Leiden, The Netherlands on total chromosomal DNA with primer R1 (Table [1](#T1){ref-type="table"}). Partial sequences of variant SCC*mec*have not yet been submitted but will be classified in further studies according to the recommendations of the International working group on the classification of staphylococcal cassette chromosome elements \[[@B11]\].
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